Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > comgrats

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Nov 26, 2023 12:24pm

199 Views

Post# 35753438

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:comgrats

If you're following, you see that costs are being kept in check. You have to spend money - no choice in that matter. That's why they cashed up like they did. Oh, the whipping the company took for going to market for that much cash - people were blind to the need.

Also - you can't say money has been wasted on other drugs. As we've seen, there's a lot of learning happening during each of these drugs - related to the active ingredients ... and ... interations with H2S ... and ... regarding H2S alone. In some respects ... running blind here because of how little is really understood.

I could take your comments and use the same logic to say ... can't believe Wallace first chased NO, only to end up at H2S. What a waste of money chasing NO. Stepping stones my friend - needed stepping stones.

You don't want only one last shot.
You want to know where you're going and where you can go - especially if you believe in the present direction and any offshoots that it's creating as opportunties.

We didn't get to H2S without spending money. We didn't get to amophous without spending money. We didn't get here without spending millions on liver experts.

And ... in drug development ... we are no where until we are somewhere.

Sure we have to watch the money - but - we have to keep spending it to create the future.

In my opinion, I'm very happy with the way this is moving forward. It's been quite a journey so far and I'm guessing ... we haven't seen anything yet. So much to still happen in 2023 and 2024. Some will be behind the scenes and others will be obvious.

I don't worry so much about the spend as I do about the perfect storm. That storm includes OTENA, it includes a known and desired direction with the funnel, it includes the patent cliff and the many issues coming during 2023-2032. It includes the downward pressure on drugs by government - and - it includes devistating outcomes from existing pain drugs, presently on the market. Can we make people healthier, increase life expectancy and do it at a reasonable cost? Can OTENA usher in other future drugs because it brings in the cash to make it happen?

That's what we're all waiting to see.

The answer is simple - either "yes" or "no."

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for June 13, 2024